Does Medicare Advantage (Any Carrier) Cover Addyi (Flibanserin)?

What Is Flibanserin and Why Does Coverage Matter?

Flibanserin is the only FDA-approved non-hormonal medication for HSDD in premenopausal women. The drug acts as a serotonin 1A receptor agonist and serotonin 2A receptor antagonist, modulating dopamine and norepinephrine in the prefrontal cortex rather than altering sex hormone levels. The FDA approved Addyi on August 18, 2015, making it the first drug in this class to reach the U.S. market.

Coverage decisions affect real clinical outcomes. An estimated 10% of premenopausal women in the United States meet diagnostic criteria for HSDD, yet treatment rates remain low partly because of cost barriers. Epidemiologic data from the National Institutes of Health document HSDD as the most common female sexual dysfunction diagnosis in this age group. When a medication costs $880 per month and insurance does not pay, many patients simply go without. Understanding exactly where Medicare Advantage stands on Addyi coverage helps prescribers counsel patients before they leave the office with a prescription that may not be fillable.

Does Any Medicare Advantage Plan Cover Addyi?

Coverage is nearly nonexistent across all Medicare Advantage Part D formularies. Addyi does not appear on the formularies of major national carriers, including UnitedHealthcare, Aetna, Humana, BCBS affiliates, and Cigna-HealthSpring, as of the 2025 plan year. A small number of regional plans have historically listed it under specialty tiers with a prior authorization requirement, but approvals at that step are rare.

The core problem is that CMS does not mandate coverage of sexual dysfunction medications under Part D. Under 42 C.F.R. § 423.120(b)(2) and the CMS Part D formulary guidance, plans have broad discretion to exclude drugs they classify outside the six protected classes (antidepressants, antipsychotics, anticonvulsants, immunosuppressants, antiretrovirals, antineoplastics). Flibanserin falls outside all six. Plans therefore exclude it without triggering any federal formulary adequacy penalty.

A second structural barrier: flibanserin targets premenopausal women. Medicare beneficiaries are predominantly 65 and older, and true premenopausal status at that age is uncommon. Plans have little actuarial incentive to negotiate a preferred-tier placement for a drug with limited expected utilization in their enrolled population. This means that even in years when a regional plan does list Addyi, it typically appears on a specialty or non-preferred brand tier with a prior authorization wall that is difficult to clear.

CMS guidance on Part D excluded drug categories confirms that medications primarily indicated for sexual dysfunction are among the categories plans may exclude entirely.

Prior Authorization Criteria for Addyi on Medicare Advantage

On the minority of plans that list Addyi at all, prior authorization criteria are demanding. A prescriber submitting a PA request should expect to document all of the following:

The patient must carry a confirmed HSDD diagnosis established by a qualified clinician, typically using a validated instrument such as the Female Sexual Function Index (FSFI) or the Decreased Sexual Desire Screener (DSDS). The DSDS was validated in a 2010 study published in the Journal of Sexual Medicine as a four-item screener with sensitivity of 85% and specificity of 71% for HSDD in premenopausal women.

The patient must be premenopausal. Plans almost always require documentation of menstrual cycle regularity or hormonal confirmation of premenopausal status (FSH below 40 mIU/mL and estradiol above 20 pg/mL are common thresholds, though plan-specific criteria vary).

The prescriber must confirm absence of contraindications, particularly concurrent use of moderate-to-strong CYP3A4 inhibitors, which can raise flibanserin plasma levels several fold and increase hypotension risk. The FDA drug label for Addyi includes a boxed warning specifically for this interaction and for alcohol-potentiated hypotension.

Step therapy is sometimes imposed: a plan may require documented failure of psychotherapy or a trial of bupropion before approving flibanserin. That requirement has no regulatory backing in FDA labeling, but plans can impose it under their own utilization management policies.

Clinical Evidence Behind the Drug: What the BEGONIA Trial Showed

The BEGONIA trial (N=1,378) published in the Journal of Sexual Medicine in 2014 remains one of the two key randomized controlled trials supporting Addyi's approval. Derogatis et al. (2014) showed that flibanserin 100 mg once daily at bedtime produced a statistically significant increase in satisfying sexual events (SSEs) compared with placebo over 24 weeks (least-squares mean change: +2.5 SSEs per month for flibanserin vs. +1.5 for placebo; P<0.001). The drug also significantly reduced distress related to low sexual desire on the Female Sexual Distress Scale-Revised (FSDS-R).

A second trial, SNOWDROP (N=949), produced directionally consistent results. Katz et al. (2013) in Menopause reported a mean increase of 0.8 SSEs per month above placebo, with significant improvements in desire and reductions in distress. The effect size is modest but clinically meaningful for women who report high baseline distress.

These trials formed the basis of the FDA advisory panel review and ultimate approval. The agency required a Risk Evaluation and Mitigation Strategy (REMS) program at approval, which was later modified. Current REMS details are available through FDA's MedWatch database.

Despite this evidence, none of the Medicare Advantage carriers have used the clinical data as a reason to add Addyi to their formularies, because the formulary exclusion is driven by benefit-category classification rather than clinical efficacy determinations. Plans do not dispute that the drug works for HSDD; they simply place it in a category they are permitted to exclude.

Step Therapy Requirements and How to Address Them

Step therapy for flibanserin is not standardized across carriers. Where it exists, the most common first-step requirement is documented psychotherapy, specifically cognitive behavioral therapy (CBT) or sex therapy with a licensed provider. A 2019 Cochrane review of psychological interventions for HSDD found moderate evidence supporting CBT for female sexual dysfunction, making this a clinically defensible requirement on its face.

The practical problem: finding a sex therapist who accepts Medicare is difficult. Many licensed sex therapists operate outside insurance networks. A patient who cannot access a covered therapist is effectively blocked from satisfying the step requirement, even if she and her physician believe pharmacotherapy is the right first-line choice.

Bupropion is sometimes listed as a step therapy alternative despite having no FDA indication for HSDD. A small RCT published in Journal of Sex and Marital Therapy (Segraves et al., 2004) found bupropion SR 150-300 mg improved sexual desire in women with HSDD, but sample sizes were small (N=51) and the evidence base is far thinner than that for flibanserin. Prescribers contesting a step-therapy requirement on the grounds that bupropion lacks an FDA indication for HSDD should document that reasoning explicitly in their PA letter.

Federal law under the Step Therapy Reform provisions in the 21st Century Cures Act and CMS guidance do require Medicare Advantage plans to allow exceptions to step therapy when a clinician determines the step drug is contraindicated, likely to cause adverse effects, or has been tried and failed. If your patient has a history of a seizure disorder, an eating disorder, or bipolar depression, bupropion may be contraindicated, and that contraindication is a valid step-therapy override basis.

How to Appeal a Medicare Advantage Denial of Addyi

Denials follow a defined federal process with tight deadlines. Missing a deadline can forfeit appeal rights at that level.

Level 1: Plan Internal Redetermination. The plan must issue a decision within 60 days for standard requests or 72 hours for expedited requests. Submit a physician statement explaining medical necessity, the BEGONIA and SNOWDROP trial data, and a summary of why step therapy alternatives are inappropriate or insufficient. CMS guidance on Part D appeals outlines the required plan response timelines and member notification requirements.

Level 2: Qualified Independent Contractor (QIC) Review. If the plan upholds the denial, request review by an independent QIC within 60 days of the plan's written denial notice. The QIC has 7 days for expedited reviews and 60 days for standard reviews.

Level 3: MAXIMUS Federal External Review. MAXIMUS Federal Services operates as the Independent Review Entity (IRE) for Medicare Part D. CMS publishes the current IRE contact information and process. MAXIMUS reviews the complete clinical record and plan documentation. Overturn rates at this level vary by drug category, but having a detailed physician declaration and peer-reviewed citations materially improves the file.

Levels 4 and 5: ALJ Hearing and Medicare Appeals Council. These apply only if the amount in controversy exceeds CMS thresholds (currently $180 for an ALJ hearing as of 2025). A 12-month supply of Addyi at $880/month far exceeds that threshold.

The strongest appeal letters include four elements: (1) a patient-specific clinical narrative documenting HSDD severity with a validated scale score, (2) documentation that contraindications to step-therapy alternatives exist, (3) peer-reviewed citations to the key trials, and (4) a direct reference to the plan's own formulary exception policy language. Physicians submitting appeals should request the plan's complete utilization management criteria under their right to those documents under CMS regulations.

Manufacturer Savings Card: Why It Cannot Be Used With Medicare Advantage

The Addyi manufacturer savings card offered through Sprout Pharmaceuticals cannot be applied to any prescription covered or potentially covered by a federal health program, including Medicare Part D and Medicare Advantage. This restriction is not a company policy choice. It reflects federal anti-kickback statute requirements that prohibit manufacturers from subsidizing cost-sharing for federal beneficiaries.

Using a manufacturer coupon to satisfy a Medicare cost-share obligation would constitute an illegal inducement under 42 U.S.C. § 1320a-7b(b). The OIG has issued multiple advisory opinions confirming this prohibition. A pharmacist who attempts to apply the savings card to a Medicare Advantage claim will receive a claims rejection at the point of sale.

This means the $880 list price is the real price for most Medicare Advantage beneficiaries, with no manufacturer offset available. Patients who need financial assistance must pursue the manufacturer's separate patient assistance program, which is income-based and not tied to cost-sharing.

Cash-Pay and Alternative Access Pathways

Because coverage is rarely achievable, prescribers should discuss alternatives during the same visit as the Addyi conversation.

Sprout Pharmaceuticals offers a patient assistance program for uninsured or underinsured patients meeting income criteria. Details and income thresholds change periodically; direct patients to the current program page rather than relying on printed office materials that may be outdated.

Telehealth platforms that operate outside Medicare billing can write prescriptions for flibanserin and connect patients to 340B-adjacent pharmacies or compounding pharmacies. 503A compounding pharmacies may compound flibanserin-based formulations, though the FDA has not evaluated compounded versions for bioequivalence, and physicians should document the informed consent discussion. FDA guidance on compounding from 503A pharmacies notes that compounded drugs are not FDA-approved and may differ in potency, purity, or stability.

GoodRx and similar discount programs are not subject to the federal anti-kickback restrictions that apply to Medicare beneficiaries using manufacturer coupons. However, using a GoodRx coupon requires billing outside Medicare entirely, meaning the cost does not count toward the Part D out-of-pocket maximum. Some patients with high drug spending elsewhere in their plan year will prefer to stay within Medicare; others will find the cash discount more practical. Prescribers should walk patients through both calculations.

Prescribing Reminders: Safety Profile and Drug Interactions

Flibanserin is taken once daily at bedtime. The FDA-approved labeling specifies bedtime administration to reduce hypotension and sedation risk during waking hours. The boxed warning covers two risks: hypotension with syncope when combined with alcohol, and dangerous drug interactions with CYP3A4 inhibitors.

Common moderate-to-strong CYP3A4 inhibitors relevant to women who may also use hormonal contraceptives include fluconazole, ketoconazole, and clarithromycin. Hormonal contraceptives themselves are weak CYP3A4 inhibitors but at typical doses do not raise flibanserin levels to dangerous ranges; pharmacokinetic data in the full prescribing information show a 1.4-fold increase in flibanserin AUC with oral contraceptives, which FDA did not consider clinically significant.

CNS depressants including benzodiazepines and sleep aids, commonly prescribed in Medicare-eligible populations, potentiate sedation. Prescribers should conduct a full medication reconciliation before initiating.

The recommended evaluation period is 8 weeks at the 100 mg bedtime dose. FDA guidance on the prescribing information states that if the patient does not report a benefit after 8 weeks, the drug should be discontinued. Continuing beyond 8 weeks without documented response does not improve the clinical case and may undermine any appeal filed on the basis of ongoing need.

What Prescribers Should Tell Patients Before Writing the Prescription

Setting accurate expectations reduces downstream frustration. The conversation should cover five points.

First: Medicare Advantage almost certainly will not cover this drug. Prepare the patient for a likely denial before she submits the prescription.

Second: The list price is $880 per month. There is no manufacturer coupon option within Medicare. Explore whether the patient assistance program income threshold applies.

Third: An appeal is worth filing if the patient has documented HSDD severity on a validated scale and clear reasons why step-therapy alternatives are contraindicated or insufficient. The BEGONIA trial data and the FDA approval provide strong appeal support material.

Fourth: Compounded flibanserin from a 503A pharmacy is a lower-cost option but carries regulatory uncertainty about bioequivalence. Document the discussion.

Fifth: Response takes at least 8 weeks to assess properly. Even if a patient obtains access through cash pay or patient assistance, she needs to understand the trial period.

Endocrine Society clinical practice guidelines on female sexual dysfunction provide a framework prescribers can reference when documenting medical necessity, establishing that HSDD is a recognized clinical condition warranting pharmacologic treatment in patients who have not responded to psychotherapy or who have contraindications to psychologic treatment.

How the 2025 Part D Redesign Affects Addyi Access

The Inflation Reduction Act Part D redesign took full effect in 2025, capping out-of-pocket costs at $2,000 annually for covered drugs. That cap applies only to drugs on a plan's formulary. Because Addyi is excluded from virtually all formularies, the $2,000 cap does not help Addyi patients. The redesign also expanded the Low Income Subsidy (LIS/Extra Help) program, but again, LIS pays cost-sharing only for covered formulary drugs.

CMS published the 2025 Part D benefit parameters confirming these coverage parameters. The cap is genuinely useful for patients on covered specialty drugs. For Addyi, the structural exclusion problem predates and survives the benefit redesign.

One indirect effect of the redesign: some plans have reorganized their formulary tiers and added or dropped drugs as they renegotiated manufacturer rebates under the new structure. Prescribers should verify formulary status each plan year rather than assuming last year's exclusion still applies, because a regional plan may have changed its policy.

Summary Table: Medicare Advantage Coverage Decision Points

| Decision Point | Typical Outcome | Action | |---|---|---| | Formulary status | Not covered | Check specific plan formulary annually at Medicare Plan Finder | | Prior authorization | Required if listed; usually denied | Submit with FSFI score, premenopausal labs, CYP3A4 contraindication data | | Step therapy | Sometimes bupropion or psychotherapy required | Document contraindications; invoke 21st Century Cures exception | | Internal appeal | Usually upheld | Submit BEGONIA / SNOWDROP citations, validated scale scores | | MAXIMUS external review | Variable; stronger with clinical documentation | Include full prescriber declaration and plan's own UM criteria | | Manufacturer coupon | Prohibited under anti-kickback law | Direct patient to income-based PAP instead | | Cash pay | $880/month list price | Evaluate GoodRx pricing outside Medicare billing |

Check the plan's Evidence of Coverage document each January for any formulary changes. If a plan does add Addyi mid-year, beneficiaries can request a formulary exception under CMS regulations at 42 C.F.R. § 423.578.